Similar to the subcutaneous tumours, ablation of LRRC15+ CAFs in orthotopic pancreatic tumours significantly improved tumour control and synergized with anti-PDL1 to further reduce tumour burden (Fig. 4l and Extended data Fig. 7b). Here, LRRC15 is linked to pancreatic neoplasm.